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From the Editor’s Desk
THE TREE OF HIPPOCRATES
Beside the drive leading to the United 
States National Library of Medicine 
(NLM) stands the Tree of Hippocrates. 
Given to the US by the people of the 
Greek island of Cos in the early 1960s, 
this tree was grown from a cutting from 
the very tree under which, as legend 
would have it, Hippocrates conducted 
his classes.
The library’s links with medicine’s 
history continue with its extraordinary 
collection of historical books. These 
include Vesalius’ ground-breaking exposé 
of human anatomy (1543), Ambroise Paré’s 
magnus opus on his surgical techniques 
and wisdom (1585), Harvey’s 
revolutionary unravelling of the circulation 
(1628), Morgagni’s clinicopathological 
observations that launched modern 
pathology (1761), and Jenner’s seminal 
treatise on smallpox (1798). There are also 
works by Galen, Paracelsus, Boerhaave and 
Osler, among others.
To see, touch and read these original 
tomes is to connect with the growth of 
medical science and practice through the 
ages, and to reflect on the endeavours of 
physicians as their questioning moved 
from, Who caused this illness? to, What is 
the illness, why does it occur and what can 
be done?
Modern medicine’s overwhelming 
preoccupation with these questions is 
mirrored in the sheer enormity of the 
NLM’s immediate neighbour, the National 
Institutes of Health (NIH). NIH’s Bethesda 
campus is a scientific metropolis of 19 
institutes and seven centres, in which 
almost 6000 scientists work, supported 
by about 10% of the annual NIH budget 
of US$28 billion!
Early this year, when visiting the NLM 
and standing by the Tree of Hippocrates, I 
could not help thinking how little medical 
history is treasured and taught in our 
medical schools, and how today’s 
reductionistic style of medicine has 
diminished the holistic approach taught so 
long ago under a tree on the island of Cos.
Martin B Van Der WeydenMJA • Volume 183 Number 5 • 5 September 2005 275
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Letters
Depressed youth, suicidality 
and antidepressants
Robert D Goldney
Professor of Psychiatry, University of Adelaide, The 
Adelaide Clinic, 33 Park Terrace, Gilberton, SA 5081. 
Robert.goldney@adelaide.edu.au
TO THE EDITOR: Two recent items in the
Journal might potentially lead to misinter-
pretation of the evidence on managing
depression in young people.
The first was the book review entitled
Darker side of “wonder drugs” by Jureidini1 in
which there was no disclosure that the
author of the review is president of Healthy
Skepticism, a body which has been quite
strident in its opposition to antidepressant
therapy. The second was the unattributed
comment in the editorial by Rey and Dudley
describing “parents who believe their chil-
dren killed themselves because they were
taking SSRIs [selective serotonin reuptake
inhibitors]...”,2 which may imply subtly
that this has occurred frequently.
In a review of the United Kingdom General
Practice Research Database of more than
three million people,3 there were no suicides
among the 6976 aged 10–19 years who had
been prescribed one of two SSRIs or two
tricyclic antidepressants; however, 15 people
in that age group who had not received an
antidepressant drug died by suicide. Further-
more, in a review of 14857 suicides in
Sweden, of the 52 involving people under 15
years, no SSRIs were detected, and in the 15–
19-years age group, those taking SSRIs had a
lower relative risk of commiting suicide than
those taking other antidepressants.4
Clinicians with responsibility for children
and adolescents can be reassured by these
data, and also by the fact that the American
Food and Drug Administration “black box”
warning (their most potent warning) about
antidepressants has recently been modified.5
Furthermore, the American Academy of
Child and Adolescent Psychiatry and the
American Psychiatric Association have pro-
vided a new resource about the use of
medication in treating childhood and ado-
lescent depression,6 which has been
endorsed by over a dozen United States
organisations comprising a “national coali-
tion of concerned parents, providers, and
professional associations”. This should allay
questions that have rightly been raised, but
that have been answered in favour of the
judicious use of antidepressants, along with
other therapeutic measures for children and
adolescents with severe depression.
In view of the strong association between
child and adolescent mood disorders and
suicide,7 the above research findings and the
recommendations of respected professional
bodies raise the issue of potential legal
action for not at least trialling antidepressant
medication in young people with severe
depression if non-pharmacological measures
are ineffective.
Competing interests: I have received honoraria
and research grants from a number of pharmaceu-
tical companies for presentations and research on
depression.
1 Jureidini JN. Darker side of “wonder drugs” [book
review]. Med J Aust 2005; 182: 293. 
2 Rey JM, Dudley JM. Depressed youth, suicidality
and antidepressants. Med J Aust 2005; 182: 378-
379. 
3 Jick H, Kaye JA, Jick SS. Antidepressants and the
risk of suicidal behaviors. JAMA 2004; 292: 338-343.
4 Isacsson G, Holmgren P, Ahlner J. Selective serot-
onin reuptake inhibitor antidepressants and the risk
of suicide: a controlled forensic database study of
14857 suicides. Acta Psychiatr Scand 2005; 111:
286-290.
5 Hanson E. AACAP/APA Press conference intro-
duces new guides for educating parents, consum-
ers about antidepressants. Am Acad Child Adolesc
Psychiatry News 2005; 36: 60-61.
6 American Psychiatric Association and American
Academy of Child and Adolescent Psychiatry. The
use of medication in treating childhood and adoles-
cent depression: information for patients and fami-
lies. Available at: http://www.parentsmedguide.org
(accessed May 2005).
7 Shaffer D, Gould MS, Fisher P, et al. Psychiatric
diagnosis in child and adolescent suicide. Arch Gen
Psychiatry 1996; 53: 339-348. ❏
Peter R Mansfield,* Melissa K Raven,† 
Jon N Jureidini‡
*Research Fellow, University of Adelaide, SA; 
†Lecturer, Flinders University, Adelaide, SA; ‡Head, 
Department of Psychological Medicine Women's and 
Children's Hospital, Adelaide, SA.
peter.mansfield@adelaide.edu.au
TO  THE E DITOR:  Rey and Dudley cite
clinical experience as the basis of their
recommendation of selective serotonin
reuptake inhibitors (SSRIs) — chiefly fluox-
etine — for youth with severe depression
plus severe impairment or failure of non-
drug therapy.1 They do not discuss the
evidence on efficacy because they claim that
it is “ambiguous enough for scholars to be
divided”. It is true that industry-funded
scholars are continuing to suggest that SSRIs
(chiefly fluoxetine) provide a worthwhile
benefit.2 However, the evidence is unambig-
uous. The four published comparisons of
fluoxetine versus placebo for children and
adolescents have all been negative on their
pre-specified primary endpoints.3,4 A tiny
average benefit is likely, but the magnitude
of this benefit is unlikely to exceed the
magnitude of less frequent but more severe
harms. Furthermore, the common clinical
impression of worthwhile benefit is to be
expected given the large average improve-
ments seen in placebo groups.
Rey and Dudley speculate that psycho-
social treatments may be less effective with
uncooperative teenagers.1 However, that
group may also be at higher risk of the
dangers of intermittent use of, and overdos-
ing with, antidepressant drugs.
Rey and Dudley cite Timimi’s critique of
the concept of childhood depression5 as
supporting “treating depression primarily as
a moral or social problem”. However,
Timimi did not even allude to depression as
a moral problem, and advocated a multi-
perspective approach that normalises emo-
tional responses to adverse life experiences
and includes interventions addressing bio-
logical factors, such as diet, exercise, and
cognitive  abilities. Rey and Dudley use a
related straw-man argument in their final
sentence when they suggest that the only
alternatives to SSRIs are tricyclic antidepres-
sants, victim blaming, and non-treatment.
Rey and Dudley deny being influenced by
the gifts and funding that they have received
from drug companies. There is compelling
evidence that gifts and funding are effective,
on average, for influencing beliefs, especially
among people who have an illusion of invul-
nerability.6 We are not aware of any way that
any individual can know that he or she has
not been influenced.
Competing interests: We are all office bearers in
Healthy
  Skepticism, an international non-profit
organisation whose main aim is to improve health
by reducing harm from misleading drug promo-
tion.
1 Rey JM, Dudley MJ. Depressed youth, suicidality
and antidepressants. Med J Aust 2005; 182: 378-
379. 
2 March JS, for the TADS Group. Authors of TADS
study reply to letter raising concerns. BMJ 2005;
330: 730-731.
3 Jureidini JN, Doecke CJ, Mansfield PR, et al. Effi-
cacy and safety of antidepressants for children and
adolescents. BMJ 2004; 328: 879-883.
4 Jureidini J, Tonkin A, Mansfield PR. TADS study
raises concerns. BMJ 2004; 329: 1343-1344.
5 Timimi S. Rethinking childhood depression. BMJ
2004; 329: 1394-1396.
6 Katz D, Mansfield P, Goodman R, et al. Psychologi-
cal aspects of gifts from drug companies. JAMA
2003; 290: 2404-2405. ❏276 MJA • Volume 183 Number 5 • 5 September 2005
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Joseph M Rey,* Michael J Dudley†
*Professor, Psychological Medicine, University of Syd-
ney, PO Box 142, North Ryde, NSW 1670. †Senior 
Lecturer in Psychiatry, University of New South Wales, 
Randwick, NSW.
 jrey@mail.usyd.edu.au
IN REPLY: The data available are inconclu-
sive, but suggest that treatment with selec-
tive serotonin reuptake inhibitors (SSRIs)
may increase the short-term (less than 14
weeks) risk of suicidal thoughts or self-harm
in children and adolescents slightly, by
about 2%. However, SSRI treatment may
actually decrease the number of completed
suicides,1 as Goldney also highlights. To
show whether SSRIs influence the risk of
completed suicide, a rare event, requires a
randomised trial including up to two million
individuals.2 This will not happen. Hence,
clinicians must rely on accumulated data
from experimental, epidemiological, and
observational studies. Disagreements about
interpretation will doubtless continue.
In response to Mansfield and colleagues,
we personally know of media reports influ-
encing some practitioners to revert to using
tricyclic antidepressants, and child psychia-
trists to avoid treating depressed adoles-
cents. We do not shrink from our
interpretation of the implications of Timimi’s
reconceptualisation of “depression” as
“unhappiness”. Regardless of how child-
hood depression is classified or named, we
remain concerned that the impetus for clini-
cians to diagnose and treat it not be lost. Its
social correlates include stigma and racism,
which often involve seeing mental health
problems as moral failures of character.
Our view is that fluoxetine shows a
favourable harm–benefit profile in moderate
to severe depression. According to the Treat-
ment for Adolescents with Depression
study,3 which was not funded by drug com-
panies, four children need to be treated with
fluoxetine for one to show much or very
much improvement attributable to medica-
tion. This compares with having to treat 21
children for one to display a widely defined
harm-related event. The numbers improve
further when fluoxetine is combined with
cognitve behavioural therapy (3 and 50,
respectively). Pending new studies, clini-
cians would be unwise to ignore these data
when treating serious depression in young
people, a recurring illness that produces
much suffering, physical and psychosocial
disability, and suicide (odds ratio estimates
ranging from 11.0 to 27.0).4 Our opinions
are consistent with those of the recently
released joint clinical guidance by the col-
leges of psychiatrists, general practitioners,
and physicians.5
Mansfield and colleagues suggest that our
editorial’s content might have been influ-
enced by drug company gifts. We provided
the educated readers of the Journal with
information to judge this for themselves.
Competing interests: Joseph Rey was a member
of the advisory committee for Strattera (Eli Lilly)
and Concerta (Janssen-Cilag) and was funded by
Eli Lilly to attend an international conference.
Michael Dudley attends Pfizer-sponsored peer
review dinners, and has (before the recent debates
about drug company gifts) received bags, pens,
and a CD.
1 Isacsson G, Holmgren P, Ahlner J. Selective sero-
tonin reuptake inhibitor antidepressants and the
risk of suicide: a controlled forensic database study
of 14857 suicides. Acta Psychiatr Scand 2005; 111:
286-290.
2 Gunnell D, Saperia J, Ashby D. Selective serotonin
reuptake inhibitors (SSRIs) and suicide in adults:
meta-analysis of drug company data from placebo
controlled, randomised controlled trials submitted
to the MHRA’s safety review. BMJ 2005; 330: 385-
388.
3 Treatment for Adolescents with Depression Study
(TADS) Team. Fluoxetine, cognitive-behavioral ther-
apy, and their combination for adolescents with
depression. JAMA 2004; 292: 807-820.
4 Beautrais A. Risk factors for suicide and attempted
suicide among young people. Aust N Z J Psychiatry
2000; 34: 420-436.
5 Royal Australian and New Zealand College of Psy-
chiatrists, Royal Australian College of General Prac-
titioners and Royal Australasian College of
Physicians. Clinical guidance on the use of antide-
pressant medications in children and adolescents.
Available at: http://www.ranzcp.org/publicarea/
pracguid.asp (accessed Jun 2005). ❏
Duncan Topliss
Chairman, Adverse Drug Reactions Advisory Commit-
tee, Therapeutic Goods Administration, Department 
of Health and Ageing, Canberra, ACT 2601. 
adrac@health.gov.au
COMMENT: Three essentially independent
reviews of the use of selective serotonin
reuptake inhibitor (SSRI) antidepressants in
children and adolescents have been under-
taken in Australia in the past 9 months.1-3
The review by the Adverse Drug Reactions
Advisory Committee1 had input from repre-
sentatives of the Royal Australian and New
Zealand College of Psychiatrists and the
Division of Paediatric and Child Health,
Royal Australasian College of Physicians
(RACP).
All three reviews noted the paucity of
information to support the efficacy of these
and other antidepressants in children and
adolescents, and the frequent observation of
increased suicidal thoughts and self-harm in
clinical trials.
The colleges’ review2 and the National
Prescribing Service Rational Assessment of
Drugs And Research (RADAR) review3 sup-
port the ADRAC advice that:
Any use of SSRIs in children and adoles-
cents with MDD [major depressive dis-
order] and other psychiatric conditions
should be undertaken only within the
context of comprehensive management
of the patient. Management should
include careful monitoring for the emer-
gence of suicidal ideation and behaviour
which may particularly develop early in
therapy, or if therapy is interrupted or
irregular because of poor compliance.
Cognitive behaviour therapy, if it is
available, may enhance the outcome in
MDD.
An SSRI should be chosen for a child or
adolescent with MDD or other psychiatric
condition only after taking into account the
recent evaluations of clinical trial data and
the Australian product information. Pre-
scribers should be aware that the marketers
of fluvoxamine and sertraline (indicated for
obsessive compulsive disorder) advise
against their use in children and adolescents
with MDD, and the marketers of citalopram,
escitalopram, paroxetine, venlafaxine and
fluoxetine warn or caution against their use
in patients aged less than 18 years for any
indication.
It is important to note that children and
adolescents who are being treated for MDD
with an SSRI should not have their medica-
tion ceased abruptly.
1 Adverse Drug Reactions Advisory Committee. Use
of SSRI antidepressants in children and adoles-
cents. Aust Adverse Drug Reactions Bull 2004; 23:
22. Available at: http://www.tga.gov.au/adr.aadrb/
aadr0412.pdf (accessed Jul 2005).
2 Royal Australian and New Zealand College of Psy-
chiatrists, Royal Australian College of General Prac-
titioners and Royal Australasian College of
Physicians. Clinical guidance on the use of antide-
pressant medications in children and adolescents.
Available at: http://www.ranzcp.org/publicarea/
pracguid.asp (accessed Jul 2005).
3 National Prescribing Service RADAR. Selective
serotonin re-uptake inhibitors in child and adoles-
cent depression. April 2005. Available at: http://
www.npsradar.org.au/npsradar/content/SSRIs.pdf
(accessed Jul 2005). ❏MJA • Volume 183 Number 5 • 5 September 2005 277
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The crisis in mental health: the 
chariot needs one horseman
Gordon R W Davies
Psychiatrist, 33 Smith Street, Wollongong, NSW 2500.  
alienist@ihug.com.au
TO THE EDITOR: The recent editorial by
Andrews1 quotes a report suggesting that
the integration projects funded by the
Australian Government produced sub-
stantial benefits to patient care at no extra
cost. Working in an area in which one of
these projects was funded, I suggest that
such an inference is unwarranted, particu-
larly as many patients report increased
difficulty in accessing public mental
health services.
The Illawarra, being geographically cir-
cumscribed and with a relatively small med-
ical population, has always had a high
degree of interaction between services,
although it is true to say that these have
somewhat declined in recent years with
larger bureaucracies and increased privacy
concerns. In my early days in the area, there
was a monthly meeting involving police,
Youth and Community Services, the Hous-
ing Commission, school counsellors, and
hospital and community social and mental
health workers to coordinate the manage-
ment of problem families. Sadly, this no
longer occurs.
Unfortunately, the major effect of the inte-
gration project was simply to add a manage-
ment structure to the prior interaction, and
not to significantly increase it. It seemed that
the core issue was control and not service
provision. Useful coordination projects,
such as some commonality of core records,
never seemed to happen, and with the pass-
ing of the project, things have, in fact, been
worse, as fundamental community services
such as the crisis team and chronic care
components have been cut.
I have always been a strong supporter of a
more integrated approach to care, but one
that does not grow primarily from the work-
ers involved in day-to-day clinical care and
that addresses their needs is unlikely to be
lasting and successful.
1 Andrews G. The crisis in mental health: the chariot
needs one horseman. Med J Aust 2005; 182: 372-
373.  ❏
Severe peanut allergy in 
Australian children
Andrew S Kemp
Professor, Allergy Immunology and Infectious Dis-
eases, The Children’s Hospital at Westmead, Locked 
Bag 4001,Westmead, NSW 2145. 
andrewk5@chw.edu.au
TO THE EDITOR: Publicity such as that on
the recently televised “Sunday” show (Chan-
nel 9) entitled “When food can be fatal”
(http://sunday.ninemsn.com.au/sunday/
cover_stories/transcript_1770.asp), which
contained statements that “30 in every 1000
[3%] children in Australia are at risk of a
severe allergic reaction [anaphylaxis] to a
food”, and a reference to a “tsunami of
children” with serious allergies, provokes
understandable concern and anxiety.
Some perspective on this issue is
required. To determine the risk, it is essen-
tial to study a population-based cohort.
Allergies to peanuts or tree-nuts are the
most common cause of severe childhood
food anaphylaxis and death.1 Wh at i s t h e
risk for Australian children of peanut-
induced anaphylaxis that is likely to require
adrenaline?
Of a population-based cohort of 456
Tasmanian children aged 7–8 years, none
reacted to a peanut skin-prick test.2 In the
Australian Childhood Asthma Prevention
Study (CAPS),3 a high-risk cohort, 4.9% of
3 year olds were prick-test positive to
peanut (unpublished data) using a liberal
cut-off of  2mm (for clinical testing the
usual cut-off is  3mm). Perhaps the most
helpful information comes from a popula-
tion-based study of 13971 preschool chil-
dren in the United Kingdom who were
followed from birth to 6 years of age.
Forty-nine (0.35%) children had an allergic
reaction to peanut, of whom only two
(0.014%) had what was described as ana-
phylaxis.4 Thirty-six of the children under-
went formal peanut challenge, 23 reacted
and three had reactions for which adrena-
line was given. Combining these three with
the previous two gives a severe reaction
rate requiring adrenaline of 0.036%. This
suggests that, of the 49 children in the UK
study who had an allergic reaction to pea-
nut, only 10% were at risk of a severe
reaction requiring adrenaline. Only a third
to a half of children with a positive peanut
skin test will react if exposed.5 Applying
these considerations to Australian children
indicates that the proportion at risk of a
s e v e r e  p e a n u t  r e a c t i o n  i s  o n l y  0 . 2 5 %
(4.9%   1/2  5/49) even in a high-risk
cohort such as the CAPS. This would be
substantially lower in a population-based
cohort. For the cohort of 7–8-year-old
Tasmanian children referred to above, the
risk would be much less than 0.2%, con-
sidering none of 500 children was prick-
test positive to peanut allergen. There has
been a substantial increase in childhood
food allergy in recent decades;5 however,
sensationalist statements and inaccurate
figures are unlikely to be helpful in devel-
oping appropriate responses. The Australa-
sian Society of Clinical Immunology and
Allergy recently published guidelines for
the prevention of food anaphylactic reac-
tions,6 and has other useful information for
patients and medical practitioners on its
website (http://www.allergy.org.au/).
1 Kemp A. EpiPen epidemic: suggestions for rational
prescribing in childhood food allergy. J Paediatr
Child Health 2003; 39: 372-375.
2 Ponsonby AL, Dwyer T, Kemp A, et al. A prospective
study of the association between home gas appli-
ance use during infancy and subsequent dust mite
sensitization and lung function in childhood. Clin
Exp Allergy 2001; 31: 1544-1552.
3 Peat JK, Mihrshahi S, Kemp AS, et al. Three-year
outcomes of dietary fatty acid modification and
house dust mite reduction in the Childhood Asthma
Prevention Study. J Allergy Clin Immunol 2004; 114:
807-813.
4 Lack G, Fox D, Northstone K, Golding J. Factors
associated with the development of peanut allergy
in childhood. N Engl J Med 2003; 348: 977-985.
5 Grundy J, Matthews S, Bateman B, et al. Rising
prevalence of allergy to peanut in children: data
from two sequential cohorts. J Allergy Clin Immunol
2002; 110: 784-789.
6 ASCIA Guidelines for prevention of food anaphy-
lactic reactions in schools, preschools and childcare
centres. Available at: http://www.allergy.org.au/
pospapers/anaphylaxis.htm (accessed Jul 2005). ❏
Universal varicella vaccination
Grant A Mackenzie
Paediatrician and Postgraduate Student, Ear Health 
and Education Unit, Menzies School of Health 
Research, PO Box 41096, Darwin, NT 0811.
grantmac@menzies.edu.au
TO  THE E DITOR:  Funding of universal
varicella zoster vaccine (VZV) at ages 18
months and 10–13 years was recently
announced in Australia. Health professionals
should be aware of a number of related issues.
Varicella vaccination was recommended
in the United States from 1996 for all chil-278 MJA • Volume 183 Number 5 • 5 September 2005
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dren aged 12–18 months, with catch-up
vaccination to age 13 years. US surveillance
shows:
• Decreased varicella mortality in all age
groups except those aged 50 years (aver-
age varicella deaths per year: 145 in 1990–
1994 versus 66 in 1999–2001).1
• Decreased varicella cases in all age
groups, with a non-significant reduction in
hospitalisations (average annual hospitalisa-
tions in three surveillance regions: 40 before
vaccination versus 14 after vaccination).2
US data on herpes zoster have not yet
been published.
There are concerns that, in the longer
term, universal varicella vaccination may
increase the incidence of adult varicella
and herpes zoster, similar to the effect of
pertussis vaccination on adult pertussis.
Modelling in the United Kingdom pre-
dicted that universal infant vaccination
would initially reduce varicella, but would
result in increases in herpes zoster 5–10
years later and adult varicella 20–40 years
later.3 In contrast, modelling of adolescent
vaccination predicted a small decrease in
varicella, but no increase in later adult
varicella.3
Varicella is generally perceived as a mild
illness, while vaccination is largely valued
for preventing serious, life-threatening con-
ditions. Anecdotal reports of low levels of
private purchase of VZV in Australia suggest
it may not be a priority for some families.
With 36% of general practitioners con-
cerned about unknown side effects of VZV,4
and public concern about vaccine adverse
events in the face of low disease rates, the
level of acceptance of universal varicella
vaccination by providers and consumers is
uncertain.
Alternatives to universal varicella vaccina-
tion were a high-risk strategy (vaccination of
children with chronic illness and family
members of high-risk individuals) or wait-
ing until US disease patterns were estab-
lished. These were real options as:
• A high-risk strategy may prevent up to
45% of paediatric hospitalisations.5
• Hospitalisation and herpes zoster con-
tribute more to health costs than treatment
in the community or acute varicella.5
• Natural infection, at the cost of disease,
immunises most of the population.
Any increase in adult varicella and herpes
zoster caused by varicella vaccination may
be alleviated by booster doses, but the
added cost, difficulty in reaching the target
population, and potential impact on com-
munity confidence in vaccination may be
significant problems. The universal varicella
vaccination program will test providers’ and
consumers’ acceptance of vaccination
against what is perceived as a mild illness.
Competing interests: I receive a research training
scholarship from the National Health and Medical
Research Council, and Wyeth Australia provides
some project funding to my institution. These
sources of support had no role in the preparation
or submission of this letter.
1 Nguyen HQ, Jumaan AO, Seward JF. Decline in
mortality due to varicella after implementation of
varicella vaccination in the United States. N Engl J
Med 2005; 352: 450-458.
2 Seward JF, Watson BM, Peterson CL, et al. Varicella
disease after introduction of varicella vaccine in the
United States, 1995-2000. JAMA 2002; 287: 606-611.
3 Brisson M, Edmunds WJ, Gay NJ. Varicella vaccina-
tion: impact of vaccine efficacy on the epidemiol-
ogy of VZV. J Med Virol 2003; 70 Suppl 1: S31-S37.
4 Milledge JT, Cooper CD, Woolfenden SR. Barriers
to immunization: attitudes of general practitioners
to varicella, the disease and its vaccine. J Paediatr
Child Health 2003; 39: 368-371.
5 Carapetis JR, Russell DMF, Curtis N. The burden
and cost of hospitalised varicella and zoster in
Australian children. Vaccine 2004; 23: 755-761. ❏
Kristine Macartney,* Peter McIntyre†
*Senior Research Fellow, †Director, National Centre 
for Immunisation Research, The Children’s Hospital at 
Westmead, Locked Bag 4001, Westmead, NSW 2145. 
peterm@chw.edu.au
COMMENT: Recently published data have
added considerably to the evidence about
the impact of varicella vaccination pro-
grams, and address many of the concerns
raised by Mackenzie.
First, in the United States where universal
varicella vaccination was recommended a
decade ago, recent data show that — despite
much slower implementation than is
expected in Australia — varicella-related
disease has declined by up to 90%, and
hospitalisation rates and deaths from vari-
cella by more than two-thirds, due to herd
immunity.1,2
Second, data have now been published on
the incidence of herpes zoster in areas of
sentinel surveillance in the US, showing no
change in age-specific rates to 2002.3 Along
with the success of a recent trial of high-
dose varicella vaccine in reducing herpes
zoster in older adults,4 these data add to
confidence that any increase in herpes zoster
— as predicted in some models — will be
detected and effectively combated by vacci-
nating people aged over 60 years. A substan-
tial allowance for surveillance of both
varicella and herpes zoster was included in
the 2005 federal budget, to accompany the
introduction of universal varicella vaccina-
tion in Australia.
Mackenzie is correct that varicella is per-
ceived by some as a mild illness, but it is
important for general practitioners to
emphasise to patients that this is incorrect.5
Each year in Australia, varicella causes
around seven to eight deaths and more than
1500 hospitalisations,6 many associated
with serious complications, such as invasive
bacterial infection, pneumonia, and
encephalitis. Although complications are
more likely in adults and immunocompro-
mised patients, 42% of hospitalisations are
in children aged 0–4 years,6 most of whom
are otherwise healthy.7
Patients can also be reassured about the
safety of varicella vaccines, as clinical trials
now date back 30 years, and more than 40
million doses of vaccine have been distrib-
uted in the US.
Mackenzie suggests alternatives to univer-
sal childhood varicella vaccination, such as
vaccination of “high risk” patients and their
families, or of adolescents alone. However,
these programs would not prevent morbid-
ity among otherwise healthy young children
and older age groups, as they would be
insufficient to generate herd immunity.
Moreover, age-based vaccination strategies
have been shown to be easier to implement
than more targeted programs. In the absence
of a publicly funded universal program, the
private market could sustain modest vari-
cella vaccination rates of around 40%–50%
in Australia.8 This would increase the
number of adolescents and adults suscepti-
ble to varicella, because of reduced exposure
to the virus and lack of vaccination; these
groups also experience greater morbidity
with infection than children.
A universal program vaccinating young
children and adolescents against varicella
offers the best current option to reduce
morbidity and mortality from this disease in
Australia. Ongoing surveillance of varicella
and herpes zoster in Australia and elsewhere
will reveal whether there is a need for
further interventions, such as a second dose
of varicella vaccine in children and high-
dose varicella vaccine to prevent herpes
zoster in older adults.
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TO THE EDITOR: The excellent report by
Harding et al in the Diagnostic Dilemmas
article in the Journal highlighted medica-
tions and conditions that may cause false
positive results of biochemical tests for
phaeochromocytoma.1 Another group of
patients, those with obstructive sleep
apnoea (OSA), may have raised urine
noradrenaline levels in the absence of a
phaeochromocytoma.
Of about 170 patients seen at a hyperten-
sion screening service at the Mater Adult
Hospital between 1998 and 2000, six had
elevated levels of urine noradrenaline and
normetadrenaline up to twice the upper limit
of the normal range on repeated testing. Five
were obese and were proven to have signifi-
cant OSA. All required at least three antihy-
pertensive drugs for reasonable control of
their blood pressure, and had normal sup-
pression of catecholamines with clonidine.
A recent report described a series of five
patients with OSA presenting as pseudo-
phaeochromocytoma who had consistently
elevated levels of noradrenaline on meas-
urement of 24-hour urinary catecholamine
levels; normetadrenaline levels were not
measured.
2 Noradrenaline levels became
normal in all five patients after treatment
with continuous positive airway pressure,
and blood pressure levels improved signifi-
cantly. Excess urinary noradrenaline, rather
than being adrenal in origin, was thought
most likely to be due to increased neuronal
release of noradrenaline from small arteries
and arterioles as a result of sympathetic
nerve activity and synaptic overflow.
In conclusion, OSA is an important
reversible cause of elevated urine noradrena-
line and normetadrenaline levels in patients
with resistant hypertension.
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IN  REPLY: We thank Morton for his letter
which highlights another group of patients in
whom raised urinary noradrenaline levels
exist in the absence of a phaeochromocy-
toma. His experience and our group of
patients1 shou ld serve as a note of caution
when making the diagnosis of phaeochromo-
cytoma. A combination of positive results of
biochemical tests, along with results of ana-
tomical and functional imaging, should serve
to minimise false positive diagnoses.
1 Harding JL, Yeh MW, Robinson BG, et al. Potential
pitfalls in the diagnosis of phaeochromocytoma.
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TO THE EDITOR: A great deal has been
said and written in recent years about
inadequate numbers in the medical work-
force. As a result, many scientific and
political articles about the need to
increase the number of medical students
and how to train them for the workforce
have been written.1,2
Yet there has been little discussion of
how those already trained and in the
workforce should be retained, or of the
rate of attrition of those in the workforce.
After 30 years as an anaesthetist, I can
recall only one positive change in my
conditions of work — the introduction of
exhaust gas scavenging. All other changes
have been negative: longer hours, greater
stress (from multiple factors, such as
increased complexity, day surgery and
admission on day of surgery) and higher
public expectations.
My motives in suggesting the need for
such research are purely selfish — having
recently retired, and enjoying the lack of
stress, I wish to be sure there is an
adequate workforce in my old age.
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grating a complex landscape. Med J Aust 2005;
182: 177-180. 
2 Kluger MT, Townend K, Laidlaw T. Job satisfaction,
stress and burnout in Australian specialist anaes-
thetists. Anaesthesia 2003; 58: 339-345. ❏
MJA